Keynote special: CureVac

15-Apr-2021 07:19

CureVac's founder Ingmar Hoerr is considered one of the pioneers in mRNA technology. For a long time, the potential of mRNAs was conceivable, but it was not until the pandemic and the first approved mRNA-based vaccines that the incredible potential behind mRNAs became clear. CureVac is currently in Phase III development of its Covid-19 vaccine, approval is planned for the summer, and a fast-track approval in Germany is currently the subject of heated political debate.

It would be the third approved mRNA vaccine worldwide, the second from a German company. Our keynote speaker Stefan Mueller is VP Pre-Cinical Development and COVID-19 Program Lead and can therefore give a perfect overview of the state of development, challenges and difficulties.

The keynote will take place on April 29 between 12 and 12:30 pm.

We value your privacy

We and our partners store or access information on devices, such as cookies and process personal data, such as unique identifiers and standard information sent by a device for the purposes described below. You may click to consent to our and our partners’ processing for such purposes. Alternatively, you may click to refuse to consent, or access more detailed information and change your preferences before consenting. Your preferences will apply to this website only. Please note that some processing of your personal data may not require your consent, but you have a right to object to such processing. You can change your preferences at any time by returning to this site or visit our privacy policy.